Compound Edaravone Injection for Acute Ischemic Stroke

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 400 participants.

Also called NCT01929096

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 400 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01929096
Other papers using this trial's data
  • Safety and efficacy of Edaravone Dexborneol versus edaravone for patients with acute ischaemic stroke: a phase II, multicentre, randomised, double-blind, multiple-dose, active-controlled clinical trial Stroke and vascular neurology, 2019-09 DOI, PubMed 31709115, PMC6812637 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01929096. Randomized; quadruple masking; primary purpose treatment. Start 2013-08 (registry gives no type); primary completion 2014-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Compound Edaravone Injection for Acute Ischemic Stroke
Condition
Acute Ischemic Stroke
Intervention (Drug)
Compound Edaravone Injection
Intervention (Drug)
Edaravone Injection
Lead sponsor
Jiangsu Simcere Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct01929096
Content hash
9ab31c966a9fea1d6d39bd2808816d63ec0b54fa11dca3f60760a39e81dc1900